Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
4.220
-0.070 (-1.63%)
Jul 9, 2026, 2:45 PM EDT - Market open
Oramed Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 13.2 | 45.95 | 54.42 | 9.06 | 40.46 | 27.46 |
Short-Term Investments | 52.64 | 84.58 | 87.51 | 152.99 | 115.26 | 118.82 |
Cash & Short-Term Investments | 65.84 | 130.53 | 141.93 | 162.05 | 155.72 | 146.28 |
Cash Growth | -49.60% | -8.03% | -12.41% | 4.06% | 6.45% | 55.39% |
Other Current Assets | 2.31 | 2.74 | 1.29 | 0.54 | 1.39 | 1.66 |
Total Current Assets | 68.15 | 133.27 | 143.22 | 162.58 | 157.11 | 147.94 |
Net Property, Plant & Equipment | 1.25 | 1.34 | 1.11 | 1.57 | 1.8 | 0.89 |
Long-Term Investments | 199.4 | 96.21 | 10.91 | 56.37 | 2.7 | 3.88 |
Other Long-Term Assets | 0.05 | 0.05 | 0.03 | 0.03 | 0.03 | 25.12 |
Total Assets | 268.85 | 230.86 | 155.28 | 220.55 | 161.64 | 177.82 |
Accounts Payable | 8.52 | 6.85 | 5.47 | 1.93 | 4.16 | 4.54 |
Short-Term Debt | - | - | - | 51.01 | - | - |
Current Portion of Leases | 0.27 | 0.29 | 0.22 | 0.27 | 0.25 | 0.13 |
Unearned Revenue | 1.47 | 1.35 | - | - | 1.34 | 2.7 |
Other Current Liabilities | 0.3 | 10.6 | - | - | - | - |
Total Current Liabilities | 10.56 | 19.09 | 5.69 | 53.21 | 5.75 | 7.37 |
Long-Term Leases | 0.49 | 0.54 | 0.16 | 0.34 | 0.65 | 0.37 |
Other Long-Term Liabilities | 19.52 | 11.49 | 4.09 | 4.1 | 4.09 | 3.47 |
Total Long-Term Liabilities | 20.01 | 12.03 | 4.25 | 4.44 | 4.74 | 3.84 |
Total Liabilities | 30.57 | 31.12 | 9.93 | 57.66 | 10.49 | 11.21 |
Common Stock | 0.49 | 0.47 | 0.48 | 0.49 | 0.48 | 0.46 |
Additional Paid-in Capital | 322.91 | 322.71 | 322.4 | 320.89 | 314.42 | 292.51 |
Retained Earnings | -85.12 | -123.44 | -176.62 | -157.56 | -163.08 | -126.52 |
Total Common Shareholders' Equity | 238.28 | 199.74 | 146.27 | 163.82 | 151.81 | 166.45 |
Minority Interest | - | - | -0.92 | -0.93 | -0.66 | 0.16 |
Shareholders' Equity | 238.28 | 199.74 | 145.35 | 162.89 | 151.16 | 166.61 |
Total Liabilities & Equity | 268.85 | 230.86 | 155.28 | 220.55 | 161.64 | 177.82 |
Total Debt | 0.76 | 0.83 | 0.37 | 51.62 | 0.89 | 0.5 |
Net Cash (Debt) | 65.08 | 129.71 | 141.56 | 110.43 | 154.83 | 145.78 |
Net Cash Growth | -49.83% | -8.37% | 28.19% | -28.68% | 6.21% | 55.74% |
Net Cash Per Share | 1.55 | 3.06 | 3.46 | 2.72 | 3.97 | 3.82 |
Book Value | 238.28 | 199.74 | 146.27 | 163.82 | 151.81 | 166.45 |
Book Value Per Share | 5.67 | 4.71 | 3.58 | 4.04 | 3.89 | 4.36 |
Tangible Book Value | 238.28 | 199.74 | 146.27 | 163.82 | 151.81 | 166.45 |
Tangible Book Value Per Share | 5.67 | 4.71 | 3.58 | 4.04 | 3.89 | 4.36 |